Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 9, 2009
- Council Starts Deliberating Online Sale of OTC Drugs
March 9, 2009
- Drugs Detected in Water from Tap Water Sources
March 9, 2009
- Fewer OTC Drug Wholesalers Report Profits despite Increases in Sales: FJPWA Survey
March 9, 2009
- 11 APIs Recommended for Approval
March 9, 2009
- NCVC Announces List of Generics Adopted by It
March 9, 2009
- Cell Cultured Vaccine for Japanese Encephalitis from BIKEN Approved
March 9, 2009
- Pharmacists' Cooperation Essential to Increase Use of Generics
March 9, 2009
- Prasugrel Approved in EU
March 9, 2009
- 2nd OTC Drug Wholesaler with Nationwide Coverage to Be Created
March 9, 2009
- GSK's Tykerb Recommended for Approval
March 9, 2009
- Sanjou General Hospital Causes Stir by Switching Back to In-house Prescriptions
March 9, 2009
- 2 Combinations of ARB and Diuretic to Become Available Soon
March 9, 2009
- Tamiflu-Resistant Influenza Virus Spreading in Japan
March 2, 2009
- National Cancer Center Posts Generics It Uses on Its Website
March 2, 2009
- No Causal Relation between Tamiflu and Abnormal Behavior: WG on Basic Studies
March 2, 2009
- HPV Vaccination Should Be Provided at Government Expense
March 2, 2009
- Sanofi-aventis Seeks Top-Five Place in Japan
March 2, 2009
- Training Courses on CKD Planned for Healthcare Providers
March 2, 2009
- Eisai Licenses Zebinix for Epilepsy from Bial-Portela
March 2, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…